MarketBeat
28 Jul 2026, 17:04 UTC · 15w ago
CTS Q2 Earnings Call Highlights
Impact · against what's priced in
CTS is seeing a significant positive catalyst from record margins and an upward revision to full-year guidance, driven by rapid diversification into medical and industrial sectors. While transportation sales remain soft, the scale of new business awards provides long-term visibility that outweighs the current cyclical dip.
- CTS+0.70
No priced-in read yet
- In context
The company raised its full-year sales guidance to $565M–$585M and adjusted EPS to $2.55–$2.70, supported by record adjusted gross margins of 41.5% and a 45% surge in medical revenue.
Read from the article alone





